Comprehensive Assessment of Colistin Induced Nephrotoxicity: Incidence, Risk Factors and Time Course

References

• Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis an off Publ Infect Dis Soc Am. 2005;40(9):1333–1341. doi:10.1086/429323
   PubMed Web of Science ®Google Scholar
• Panigrahi K, Pathi BK, Poddar N, et al. Colistin resistance among multi-drug resistant gram-negative bacterial isolates from different clinical samples of ICU patients: prevalence and clinical outcomes. Cureus. 2022;14(8):e28317. doi:10.7759/cureus.28317
   PubMed Web of Science ®Google Scholar
• Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535–543. doi:10.1097/QCO.0b013e328332e672
   PubMed Web of Science ®Google Scholar
• Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2021;163:105328. doi:10.1016/j.phrs.2020.105328
   PubMed Web of Science ®Google Scholar
• Chien H-T, Lin Y-C, Sheu -C-C, Hsieh K-P, Chang J-S. Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis. Int J Antimicrob Agents. 2020;55(3):105889. doi:10.1016/j.ijantimicag.2020.105889
   PubMed Web of Science ®Google Scholar
• Oliota AF, Penteado ST, Tonin FS, Fernandez-Llimos F, Sanches AC. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagn Microbiol Infect Dis. 2019;94(1):41–49. doi:10.1016/j.diagmicrobio.2018.11.008
   PubMed Web of Science ®Google Scholar
• Miano TA, Lautenbach E, Wilson FP, Guo W, Borovskiy Y, Hennessy S. Attributable risk and time course of colistin-associated acute kidney injury. Clin J Am Soc Nephrol CJASN. 2018;13(4):542–550. doi:10.2215/CJN.06980717
   PubMed Web of Science ®Google Scholar
• Özkarakaş H, Köse I, Zincircioğlu Ç, et al. Risk factors for colistin-associated nephrotoxicity and mortality in critically ill patients. Turkish J Med Sci. 2017;47(4):1165–1172. doi:10.3906/sag-1604-60
   PubMed Web of Science ®Google Scholar
• Abdel-Hafez Y, Siaj H, Janajri M, et al. Tolerability and epidemiology of nephrotoxicity associated with conventional amphotericin B therapy: a retrospective study in tertiary care centers in Palestine. BMC Nephrol. 2022;23(1):132. doi:10.1186/s12882-022-02770-2
   PubMed Web of Science ®Google Scholar
• Nazzal Z, Abdeljaleel F, Ashayer A, Salameh H, Hamdan Z. The rate and risk factors of acute kidney injury among cancer patients’ admissions in Palestine: a single-center study. Int J Nephrol. 2022;2022:2972275. doi:10.1155/2022/2972275
   PubMed Web of Science ®Google Scholar
• Ciftci A, Izdes S, Altintas ND. Factors determining nephrotoxicity and mortality in critical care patients receiving colistin. J Infect Dev Ctries. 2018;11(12):912–918. doi:10.3855/jidc.9443
   PubMed Web of Science ®Google Scholar
• Rashizal Sazli MR, Syed Mohamed AF, Wan Mazuan WM, Ling SM, Mahmud A, Amin Nordin S. Colistin-associated nephrotoxicity among patients in intensive care units (ICU) of hospitals in Selangor. Med J Malaysia. 2017;72(2):100–105.
   PubMedGoogle Scholar
• Gunay E, Kaya S, Baysal B, Yuksel E, Arac E. Evaluation of prognosis and nephrotoxicity in patients treated with colistin in intensive care unit. Ren Fail. 2020;42(1):704–709. doi:10.1080/0886022X.2020.1795878
   PubMed Web of Science ®Google Scholar
• Hassan MM, Gaifer Z, Al-Zakwani IS. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium. Int J Clin Pharm. 2018;40(2):444–449. doi:10.1007/s11096-018-0607-y
   PubMed Web of Science ®Google Scholar
• Grayson ML, Cosgrove SE, Crowe S, et al. Kucers’ the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs. Vol. 3. 7th ed. CRC Press; 2017.
   Google Scholar
• Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis an off Publ Infect Dis Soc Am. 2009;48(12):1724–1728. doi:10.1086/599225
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy. 2013;59(3):225–231. doi:10.1159/000356004
   PubMed Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics. 2021;13(2):162. doi:10.3390/PHARMACEUTICS13020162
   PubMed Web of Science ®Google Scholar
• Almutairy R, Aljrarri W, Noor A, et al. Impact of colistin dosing on the incidence of nephrotoxicity in a tertiary care hospital in Saudi Arabia. Antibiotics. 2020;9(8):485. doi:10.3390/antibiotics9080485
   Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients. Pharmaceutics. 2022;14(1):1266. doi:10.3390/pharmaceutics14010031
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin–meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect. 2006;12(12):1227–1230. doi:10.1111/j.1469-0691.2006.01559.x
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiot. 2020;9(10):647. doi:10.3390/ANTIBIOTICS9100647
   Google Scholar
• Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018;73(1):22–32. doi:10.1093/jac/dkx368
   PubMed Web of Science ®Google Scholar
• Poursoleiman A, Karimi-Jafari MH, Zolmajd-Haghighi Z, et al. Polymyxins interaction to the human serum albumin: a thermodynamic and computational study. Spectrochim Acta Part A Mol Biomol Spectrosc. 2019;217:155–163. doi:10.1016/J.SAA.2019.03.077
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Short-course versus long-course colistin for treatment of carbapenem-resistant A. baumannii in cancer patient. Antibiot. 2021;10(5):484. doi:10.3390/ANTIBIOTICS10050484
   Google Scholar
• Joannidis M, Druml W, Forni LG, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: expert opinion of the working group on prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med. 2017;43(6):730–749. doi:10.1007/s00134-017-4832-y
   PubMed Web of Science ®Google Scholar